• Explore /
  • Poster
  • / Efficacy and safety of 1L selpercatinib in <em>RET</em> fusion-positive NSCLC: LIBRETTO-431 East Asian subgroup analysis.

Efficacy and safety of 1L selpercatinib in RET fusion-positive NSCLC: LIBRETTO-431 East Asian subgroup analysis.

Abstract Poster

Authors

null

Ying Cheng

Jilin Cancer Hospital, Changchun, China

Ying Cheng , Herbert H. Loong , Caicun Zhou , Kazumi Nishino , Dae Ho Lee , Se-Hoon Lee , James Chih-Hsin Yang , Dan Liu , Deborah Rajakumar , Hongmei Han , Tarun Puri , Aimee Bence Lin , Koichi Goto

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Breakthrough

Session Type

Poster Session

Session Title

Poster Session B

Track

Thoracic Cancers,Breast Cancer,Gynecologic Cancer,Head and Neck Cancer,Hematologic Malignancies,Genetics/Genomics/Multiomics,Healthtech Innovations,Models of Care and Care Delivery,Viral-Mediated Malignancies,Other Malignancies or Topics

Sub Track

Targeted Therapies

Clinical Trial Registration Number

NCT04194944

Citation

J Clin Oncol 42, 2024 (suppl 23; abstr 214)

DOI

10.1200/JCO.2024.42.23_suppl.214

Abstract #

214

Poster Bd #

K9

Abstract Disclosures

Similar Posters

First Author: Martin Reck

First Author: Makoto Nishio

Poster

2024 ASCO Breakthrough

Intracranial outcomes of 1L selpercatinib in advanced <em>RET</em> fusion-positive NSCLC: LIBRETTO-431 study.

Intracranial outcomes of 1L selpercatinib in advanced RET fusion-positive NSCLC: LIBRETTO-431 study.

First Author: Minji Uh

First Author: Panpan Zhang